Sir, -The new European legislation concerning pharmacovigilance published in 2010 promotes the involvement of patients in spontaneous reporting programs of suspected adverse drug reactions (ADR) [1] . To facilitate this involvement, regulatory agencies of the European Union member states should develop websites for the electronic reporting by citizens; it should be the initiative of each country to develop paper formats and additional reporting systems, such as telephone, fax, or e-mail [2, 3] . In January 2013, the Spanish Agency of Medicines and Medical Devices (AEMPS) set up a website including an electronic form for direct reporting by citizens of suspected ADR (www. notificaram.es). In this way, the AEMPS is enforcing the new legislation and provides the Spanish population with the possibility of reporting ADRs and collaborating with the existing pharmacovigilance system [4] ; the Spanish agency has not implemented additional reporting systems for citizens so far.
The electronic format for reporting is very convenient since Internet users in Spain are mainly young and middle-aged people; in addition, the information is automatically registered in the database. However, this particular format might not facilitate reporting by people from rural areas with limited access to the Internet or elderly people.
To analyze the feasibility of this approach, we are developing a pilot study of reporting problems related to medications by citizens in Spain; this pilot study is focused on ADRs as much as on other problems related to medications. The project is a collaboration of three Spanish pharmacovigilance research groups: the University of Oviedo (Asturias), the University of Valladolid (Castilla y León), and the Galdakao Hospital (Basque Country), and it covers the population of these three Spanish regions, with a total population of 5,816,531 inhabitants according to the population census of 2012. Under the slogan "yo notifico" (I report) we have developed: 1) a website (www. yonotifico.es) linked to the website of the AEMPS for citizens to report ADRs and 2) a paper formulary: "the blue card", to report ADRs and other problems related to medications (Table 1 ). The electronic formulary encloses a field of free text (1000 characters maximum) to allow the reporter to summarize the case in their own words. The website also includes information about why, what, and how to report. From January to June 2013, we ran a promotional campaign for the project in collaboration with consumer organizations, pharmacists, town associations, ; adverse reaction associated with a health product, 1). The majority of the reports (n = 27; 75%) were received during the promotional campaign. The evolution of report reception over this time interval is summarized in Figure 1 . In the reports, the pharmacological classes most frequently involved were: psychotropic drugs (n = 16), non-steroidal anti-inflammatory drugs (n = 5), antihypertensive drugs (n = 4), and antineoplastic agents (n = 3). Organs and systems most frequently involved in the ADR were: nervous system (n = 11; 18.6%), skin and subcutaneous tissue (n = 9; 15.3%), gastrointestinal (n = 8; 13.6%), and general disorders (n = 8; 13.6%). All but one of the ADRs reported were included in the summary product characteristics. Other problems related to medications reported were: 3 related to the purchase of the medication, 2 concerning difficulty in oral administration, and 1 regarding the information included in the leaflet.
Our first reports are in line with those previously obtained in other countries [2, 3] and show the ability of the Spanish population to provide valuable information about different problems associated with medications. According to our initial experience, the main difficulty in developing spontaneous reporting by citizens is not their ability to identify ADRs or other problems related to medications, but: 1) to inform the population about the possibility of collaborating by reporting medication-related problems and 2) to be able to involve citizens in actively reporting. During our promotional campaign, we observed interest from citizens and patient associations in collaborating but also surprise discovering the new option for citizens to play an active role in pharmacovigilance. In the United Kingdom, patients have been allowed to report suspected ADRs to the Medicines and Healthcare products Regulatory Agency (MHRA) since 2005. However, street interviews performed in the population of Liverpool in 2011 found that only 6.2% were aware of the possibility of direct patient reporting [5] . Some broadcasting in the media about the benefits and risks of medicines such as statins has shown the potential to increase reporting of ADRs by patients [6] . However, the development of ways to steadily maintain the stimulus for reporting in citizens is crucial; initiatives such as the publication of a newsletter linked to the "yonotifico" website as well as seeking the support of pharmacists to report by paper formats might be useful tools to achieve this aim.
Funding
This project is supported by the Carlos III Institute, dependent on the Economy and Competitiveness Ministry of the Spanish Government (PI11-01807).
